APLS - Company ID 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$60.97M | -$53.41M | -$132.98M | -$177.62M | -$111.56M | -$153.31M |
| Capital expenditure | - | $8.00K | $293.00K | $259.00K | $86.00K | $484.00K |
| Investing cash flow | - | -$8.00K | -$293.00K | -$259.00K | -$271.95M | -$146.76M |
| Dividends paid | - | - | - |
Apellis Pharmaceuticals, Inc. reported operating cash flow of $45.33M for fiscal year 2025. That is up 151.6% from -$87.87M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$26.00M (FY 2016) to $45.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $64.00K | $274.00K | $108.21M | $391.11M | $376.70M | $1.63M |